Moreover, improvement in abnormal conditions like inflammation, cellular apoptosis, and insulin resistance advocates for the diverse pharmacological activities of PTP1B, thus presenting it as an attractive therapeutic target for conditions like NAFLD (Pan et al., 2022). Here, PTPN1 is linked to metabolic dysfunction-associated steatotic liver disease.